Core - Drug, Discovery, Design and Synthesis

核心 - 药物、发现、设计和合成

• 批准号: 8152937
• 负责人: Gunda I. Georg
• 金额: $ 112.45万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8152937
• 关键词: Animals; Arts; Bioavailable; Biological; Biological Assay; Biology; Clinical; Clinical Trials; Collaborations; Common Good; Complex; Computer Simulation; Contraceptive Agents; Core Facility; Data; Development; Digit structure; Drug Design; Environment; Future; Goals; Grant; Hormonal; In Vitro; Institution; Knowledge; Laboratories; Lead; Libraries; Male Contraceptions; Male Contraceptive Agents; Male Genital Organs; Methods; Molecular Chaperones; Na(+)-K(+)-Exchanging ATPase; National Institute of Child Health and Human Development; Peptide Elongation Factor 1; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Preparation; Procedures; Program Development; Property; Protein Tyrosine Kinase; Proteins; Recording of previous events; Reproductive Biology; Research; Research Personnel; Resolution; Resource Development; Screening procedure; Solubility; Spermatogenesis; Structure; Testing; Therapeutic; Universities; Ursidae Family; Vagina; Work; X-Ray Crystallography; aqueous; base; cell motility; combinatorial chemistry; design; drug development; drug discovery; fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether; high throughput screening; in vivo; infancy; inhibitor/antagonist; innovation; insight; pre-clinical; protein structure; research clinical testing; response; small molecule; sperm cell; sperm protein; transcription factor

3. Core Unit B: Drug Discovery, Design & Synthesis (Georg) a. Objective: The discovery and development of non-hormonal male contraceptive agents is in its infancy. However, knowledge about the basic biology of the male reproductive system has exploded and extensive biological insights provide the opportunity to initiate drug discovery and development programs. Contraceptive drugs must be highly effective, reversible, orally bioavailable or suitable for intra-vaginal application, and safe. In response to this opportunity and challenge we have assembled a core facility (Drug Discovery, Design & Synthesis Core, DDS) that will support this interdisciplinary U54 center with the expertise to discover, design, synthesize, and develop male contraceptive agents. In a highly collaborative manner with the PIs of this center, its drug development core, and the NICHD we will optimize hit and lead compounds for potency, selectivity, and pharmaceutical properties in preparation for clinical trails. The long-term goal of this center is the development of non-hormonal male contraceptive agents. For the current application we have selected several targets for drug discovery that are important for spermatogenesis, spermiation, motility and capacitation. The targets are the molecular chaperone Hsp90J3, eukaryotic elongation factor 1 a (eEF1A), Na,K-ATPase a4, Doublesex and Mab-3 related transcription factor-1 (Dmrt1), and sperm protein tyrosine kinases. In addition, it is anticipated that future junior investigators of the U54-center will work on other target proteins. The central research hypothesis for the core is that small molecule inhibitors of each of the targets can be discovered, optimized, and investigated in vitro and in vivo with the ultimate goal to bring one or more agents towards clinical trials. The investigators are well prepared to undertake this project because they have a track record of research in reproductive biology, drug discovery, drug' development, and a successful history of collaborating on the discovery and development of male contraceptive agents. The research environment for drug discovery is also excellent and provides unique facilities that are not often found at universities such as high throughput screening laboratories (KU), a combinatorial chemistry laboratory (UMN), a large-scale synthesis laboratory (UMN), an Office for Therapeutics Discovery and Development (KU), and a common Good Manufacturing Procedures (c-GMP) synthesis facility (UMN). Objective 1: Identify inhibitors for sperm-specific targets by high throughput screening and by screening of targeted libraries. In collaboration with the project PIs, we will develop assays that are suitable for high throughput screening. A compound library of over 100,000 compounds and/or smaller targeted libraries will be screened to identify small molecule inhibitors of the target proteins. Objective 2: Determine protein-inhibitor interactions by protein X-ray crystallography. The target proteins will be co-crystallized with lead compounds and the structure of the protein-hit complex(es) will be determined at atomic resolution. The structural data will be used for structure-based drug design to optimize hit compounds for potency and selectivity and for in silico screening. Objective 3: Optimize screening hits for potency and selectivity. Small molecules will be optimized for potency and selectivity, using structure-based drug design and other rational design medicinal chemistry principles. These studies will be carried out in close collaboration with the project PIs and the Drug Development Core. Compounds will be prepared, tested and then further optimized with the goal to generate single digit nanomolar inhibitors that posses about 1000-fold selectivity and aqueous solubility of >100 ¿mu¿g/ml. Objective 4: Develop lead compounds for preclinical and clinical evaluation. In collaboration with the Drug Development Core and the NICHD we will optimize the pharmaceutical properties of lead compounds in preparation for clinical trails. We will also provide large-scale amounts of lead compounds for animal studies. Our approach toward the discovery and development of non-hormonal male contraceptive agents is innovative because we have identified several highly promising targets that have not been explored for drug discovery before. We are bringing state-of-the-art drug discovery methods to bear on these projects and are looking forward to working with the other U54 centers and providing them with drug discovery and development resources and expertise that are rarely available at academic institutions. At the end of the five-year center grant we will have identified small molecule inhibitors for each of the targets, we will have co-crystallized small molecule inhibitors with the target proteins and will have used structural information about protein-inhibitor interactions for drug design. The screening hits will have been optimized for potency, selectivity, and pharmaceutical properties and we expect that at least one optimized lead compound will have been selected for clinical trials and will ultimately be commercialized for male contraception.

3。核心单元B：药物发现，设计与合成（GEORG） 一个。客观的： 非激素男性避孕药的发现和发展仍处于起步阶段。但是，关于男性生殖系统基本生物学的知识爆炸而广泛的生物学见解为启动药物发现和开发计划提供了机会。避孕药必须非常有效，可逆，口服生物利用或适用于阴道内应用，安全。 为了应对这一机会和挑战，我们组建了一个核心设施（药物发现，设计与合成核心，DDS），该设施将支持该跨学科U54中心的专业知识，以发现，设计，设计，合成和开发男性避孕药。与该中心的PI，其药物发育核心以及NICHD的高度协作方式，我们将优化命中和铅化合物，以准备效力，选择性和药物特性，以准备临床跟踪。 该中心的长期目标是开发非激素男性避孕药。对于当前的应用，我们选择了几个对药物发现的靶标，这些靶标对于精子发生，精子，运动性和电容很重要。靶标是分子链链HSP90J3，真核伸长因子1 A（EEF1A），Na，K-ATPase A4，Doublesex和MAB-3相关转录因子1（DMRT1）和精子蛋白酪氨酸酪氨酸酪氨酸酪氨酸激酶。另外，预计U54中心未来的初级研究人员将在其他靶蛋白上工作。核心的中心研究假设是，可以在体外和体内发现，优化和研究每个靶标的小分子抑制剂，其最终目标是将一个或多个试剂带入临床试验。 研究人员准备进行该项目，因为他们在生殖生物学，药物发现，药物开发以及在男性避孕剂发现和开发方面的成功历史上拥有研究记录。药物发现的研究环境也非常出色，并提供了独特的设施，这些设施在高通量筛选实验室（KU），组合化学实验室（UMN），大规模合成实验室（UMN），治疗疗法的办公室，用于治疗和发展的办公室（KU）（KU）（KU）（KU）以及常见的良好制造工具（C-GMP）umn sonstththeristeres（UMN）umn。 目标1：通过高吞吐量筛选和筛选目标文库来确定精子特异性目标的抑制剂。与PIS项目合作，我们将开发适合高通量筛查的暗杀。将筛选一个超过100,000种化合物和/或较小目标库的化合物库，以鉴定靶蛋白的小分子抑制剂。 目标2：通过蛋白质X射线晶体学确定蛋白质抑制剂相互作用。靶蛋白将与铅化合物共结晶，并将在原子分辨率下确定蛋白质冲击复合物（ES）的结构。结构数据将用于基于结构的药物设计，以优化用于效力和选择性以及在计算机筛选中的命中化合物。 目标3：优化筛选效果和选择性。小分子将使用基于结构的药物设计和其他合理设计医学化学原理来优化效能和选择性。这些研究将与PIS PIS和药物开发核心密切合作进行。将制备，测试化合物，然后进一步优化，以生成单位数字纳摩尔抑制剂，该抑制剂的选择性约为1000倍，水溶性> 100»Mu¿g/ml。 目标4：开发用于临床前和临床评估的铅化合物。与药物开发核心和NICHD合作，我们将优化铅化合物的药物特性，以准备临床踪迹。我们还将为动物研究提供大量铅化合物。 我们针对非激素男性避孕药的发现和发展的方法具有创新性，因为我们已经确定了几个较高的靶标，这些目标以前尚未探索过药物发现。我们正在带来最先进的药物发现方法来遵循这些项目，并期待与其他U54中心合作，并为他们提供在学术机构很少可用的药物发现，开发资源和专业知识。 在五年中心赠款的结束时，我们将确定每个靶标的小分子抑制剂，我们将与靶蛋白共结晶的小分子抑制剂，并将使用有关药物设计的蛋白质抑制剂相互作用的结构信息。筛选命中率将针对效力，选择性和药物特性进行优化，我们希望至少将选择一种优化的铅化合物进行临床试验，并最终将商业化以进行男性违规。